Biased for Benefit: Stimulating the world’s most popular drug targets with more nuance

From Nature Medicine, June 2017 (Image: Nick Page via Flickr)

In September 2012, a small biotech startup named Trevena unveiled preclinical trial results for its front-running compound, TRV027. The fledgling Philadelphia-based company had been going strong since its founding five years earlier, raising $24 million from investors in 2008 and securing a position in BusinessWeek’s top 15 US startups for that year. In 2010, it raised a further $35 million. Trevena was pinning its fortunes on a dramatic rewriting of cell-receptor theory that has taken place over the past three decades. Read more…

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s